Phase i study of the safety, pharmacokinetics and antitumor activity of famitinib

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 5, 2013, Pages 1043-1053

  Zhou, Aiping ^a   Zhang, Wen ^a   Chang, Chunxiao ^a   Chen, Xiaoyan ^b   Zhong, Dafang ^b   Qin, Qiong ^a   Lou, Donghua ^c   Jiang, Haoyuan ^d   Wang, Jinwan ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Jiangsu Hengrui Medicine Co Ltd   (China)

Author keywords

Antitumor activity; Famitinib; Pharmacokinetics; Phase I trial; Safety

Indexed keywords

ANTINEOPLASTIC AGENT; CD135 ANTIGEN; FAMITINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; ALOPECIA; ALVEOLAR SOFT PART SARCOMA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RASH; SENSORY DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISCOLORATION; SKIN MANIFESTATION; SOLID TUMOR; STEADY STATE; THROMBOCYTOPENIA; AGED; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; BLOOD; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; CHINA; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; HALF LIFE TIME; INCIDENCE; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; NEOPLASMS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SARCOMA; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BIOTRANSFORMATION; CARCINOMA, RENAL CELL; CHINA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; HYPERTENSION; INCIDENCE; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; POSTPRANDIAL PERIOD; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; SARCOMA; YOUNG ADULT;

EID: 84887149110     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2282-y     Document Type: Article

References (25)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342 (Pubitemid 38702844)
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125-134 (Pubitemid 46089673)
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115-124 (Pubitemid 46089672)
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
5. Demetri GD, van Oosterom AT, Garrett CR, Hilgard P, Gane E, Blanc JF et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329-1338 (Pubitemid 44528723)
6. Lou LG, Mi Y, Xu YP, Chengying Xie, Zhao HB (2011) Preclinical antitumor study of famitinib, an orally available multi-targeted kinase inhibitor of VEGFR/PDGFR/c-Kit in phase I clinical trials. In Proceedings of the 102 th annual meeting of the American Association for Cancer Research, 2011 Apr 2-6. AACR, Orlando, Florida, Abstr3604
7. Xie C, Zhou J, Guo Z, Diao X, Gao Z, Zhong D et al (2013) Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol 168(7):1687-1706
8. http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf
9. Omura GA (2003) Modified Fibonacci search. J Clin Oncol 21(16):3177
10. Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J et al (2006) Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17(3):353-358
11. Faivre S, Delbaldoc C, Vera K, Robert C, Lozahic S, Lassau N et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25-35 (Pubitemid 46630490)
12. Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS et al (2010) The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40(10):980-985
13. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M et al (2010) A Phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40(3):194-202
14. Qin S, Jin J, Guo J, Wang J, Zhou F, Huang Y et al (2012) A phase IV multicenter study of the efficacy and safety of sunitinib as first-line therapy in Chinese patients with metastatic renal cell carcinoma. Ann Oncol 23(Suppl 9):abstr851p
15. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ et al (2009) Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 41(20):67-72
16. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909-918 (Pubitemid 41103603)
17. Hudes G, Carducci M, Tomczak P, Szczylik C, Oudard S, Siebels M et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(2):2271-2281 (Pubitemid 46849157)
18. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456
19. Lee CK, Marschner IC, Simes RJ, Voysey M, Egleston B, Hudes G et al (2012) Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 18(11):3188-3196
20. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931-1939
21. Tariq Mahmood S, Agresta S, Vigil CE, Rau J, Wimberger P, Sehouli J et al (2011) Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer 129(8):1963-1969
22. Bertuzzi A, Stroppa EM, Secondino S, Pedrazzoli P, Zucali P, Quagliuolo P et al (2010) Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy. J Clin Oncol 28(15s):abstr10025
23. Palassini E, Stacchiotti S, Negri T, Brich S, Marrari A, Morosi C et al (2010) Sunitinib malate (SM) in alveolar soft sarcoma (ASPS). J Clin Oncol 28(15s):abstr10014
24. Neuhaus T, Luyken J (2012) Long lasting efficacy of Sorafenib in a heavily pretreated patient with thymic carcinoma. Target Oncol 7(4):247-251
25. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH et al (2009) Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 9:82